Study on the safety profile of Latanoprost and Timolol in primary open angle glaucoma.
Loading...
Date
2015-09
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Topical beta blockers, Timolol and the prostaglandin F2α analogue
Latanoprost are the most common prescribed medications as first line therapy. Their
safety profiles have to be compared to justify the same. The objectives of this study
were to compare the safety profile of Latanoprost with that of Timolol in the treatment
of primary open angle glaucoma.
Methods: In this randomized open label 12-week study, 60 patients were randomized
to receive either 0.005% of Latanoprost once daily in the evening or 0.5% of Timolol
twice daily. Their safety was concluded by monitoring their adverse effects during
follow-up visits at 2, 4, 6, and 12 weeks.
Results: Bradycardia was seen only in Timolol group whereas ocular adverse effects
such as periocular pigmentation, the growth of eyelashes, and conjunctival hyperemia
were seen only in Latanoprost group. Ocular discomfort was present equally in both
the groups. Foreign body sensation was seen in both the groups, but it was more
frequent in Latanoprost group. The blurring of vision was predominantly seen in
Timolol group. Corneal anesthesia was seen in one of the patients on Timolol.
Conclusions: The incidence of adverse effects was not significantly different between
Latanoprost and Timolol therapy. Both had favorable safety profiles. However,
Latanoprost has safer systemic side effects profile when compared to Timolol.
Description
Keywords
Beta blocker, Intraocular pressure, Prostaglandin analogue
Citation
Rao Sharadashri, Narayanan P V. Study on the safety profile of Latanoprost and Timolol in primary open angle glaucoma. International Journal of Basic & Clinical Pharmacology. 2015 Sep-Oct; 4(5): 966-969.